Barclays PLC Reaffirms “Equal Weight” Rating for Allergan PLC. (AGN)
Allergan PLC. (NYSE:AGN)‘s stock had its “equal weight” rating reaffirmed by Barclays PLC in a report released on Monday.
Several other brokerages have also commented on AGN. Cowen and Company set a $400.00 target price on shares of Allergan PLC. and gave the stock a “buy” rating in a research report on Thursday, June 8th. Citigroup Inc. reiterated a “buy” rating and issued a $280.00 price target on shares of Allergan PLC. in a report on Wednesday, September 20th. Mizuho reduced their price objective on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a research note on Friday, June 9th. Royal Bank Of Canada reiterated a “buy” rating and issued a $285.00 price objective on shares of Allergan PLC. in a research note on Wednesday, September 6th. Finally, Cantor Fitzgerald assumed coverage on shares of Allergan PLC. in a report on Friday, June 16th. They set a “neutral” rating and a $231.00 price objective on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the company. Allergan PLC. presently has an average rating of “Buy” and an average price target of $271.84.
Allergan PLC. (NYSE:AGN) traded up 2.823% during midday trading on Monday, hitting $210.735. 1,235,290 shares of the stock traded hands. The stock has a market cap of $70.45 billion, a PE ratio of 6.421 and a beta of 1.15. The company has a 50-day moving average of $229.79 and a 200-day moving average of $236.07. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same period last year, the firm earned $3.35 EPS. On average, equities research analysts anticipate that Allergan PLC. will post $16.22 earnings per share for the current year.
Allergan PLC. announced that its board has approved a share repurchase program on Monday, September 25th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to purchase up to 2.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.
A number of institutional investors have recently modified their holdings of the stock. Waldron LP acquired a new position in shares of Allergan PLC. in the 1st quarter valued at about $348,000. Swiss National Bank grew its holdings in shares of Allergan PLC. by 20.5% during the 1st quarter. Swiss National Bank now owns 1,329,086 shares of the company’s stock worth $317,545,000 after purchasing an additional 226,200 shares during the period. Boulegeris Investments Inc. grew its holdings in shares of Allergan PLC. by 0.8% during the 1st quarter. Boulegeris Investments Inc. now owns 31,480 shares of the company’s stock worth $7,521,000 after purchasing an additional 261 shares during the period. World Asset Management Inc grew its holdings in shares of Allergan PLC. by 3.7% during the 1st quarter. World Asset Management Inc now owns 34,865 shares of the company’s stock worth $8,330,000 after purchasing an additional 1,235 shares during the period. Finally, Morse Asset Management Inc acquired a new stake in Allergan PLC. during the 1st quarter worth approximately $1,584,000. Hedge funds and other institutional investors own 82.03% of the company’s stock.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.